Benefit of anti-TNFalpha treatment for nephrotic syndrome in a patient with juvenile inflammatory bowel disease associated spondyloarthropathy complicated with amyloidosis and glomerulonephritis

Efficacy of scheduled infliximab maintenance therapy on systemic amyloidosis associated with crohnʼs disease

“…A previous study suggested that infliximab might act on systemic amyloidosis by improving glomerular inflammation and permeability and blocking serum amyloid A protein production. 8 Notably, Boscá et al 6 showed a decrease in amyloid deposits in the colonic mucosa after 5 years of treatment with infliximab. Many CD patients have suffered from systemic amyloidosis.…”

“…A 35-year-old male CD patient was admitted to our hospital on January 8 we suspected an association of secondary amyloidosis; therefore, an examination for amyloidosis was performed. Consequently, AA-type amyloid deposition was systemically detected in the biopsy specimens from his colon, terminal ileum, and kidney.…”

Tocilizumab for the Treatment of AA Amyloidosis

“…Frequency of diarrhea was markedly reduced in 2 of the 3 patients with digestive tract amyloidosis, while amyloidosis progressed in 7 patients and was stabilized in 5 patients. Verschueren et al described a patient with AA amyloidosis secondary to juvenile spondyloarthropathy treated with 3 mg/kg of infliximab (Verschueren et al, 2003). After six months, CRP returned to normal in conjunction with a reduction in proteinuria and after nine months urine analysis showed normal findings and protein excretion had been reduced.…”

Drug-Induced Nephrotoxicity in Inflammatory Bowel Disease

“…Although previous reports suggested a possible beneficial role of TNFα inhibitors in the treatment of GN [56,57,58,59], more recent reports and greater experience with TNFα inhibitors raised intriguing questions concerning the efficacy of TNFα inhibitors in GN as well as demonstrating a possible causative role in the emergence of renal complications such as GN. To our knowledge, GN occurred in at least 19 patients (most of them developing lupus nephritis), during treatment with anti-TNFα [60,61,62,63,64,65,66,67,68], as indicated in table 2.…”